Constant Transmission Properties of Variant Creutzfeldt-Jakob Disease in 5 Countries
Abigail B. Diack, Diane Ritchie, Matthew Bishop, Victoria Pinion, Jean-Philippe Brandel, Stephane Haik, Fabrizio Tagliavini, Cornelia Van Duijn, Ermias D. Belay, Pierluigi Gambetti, Lawrence B. Schonberger, Pedro Piccardo, Robert G. Will1, and Jean C. Manson1
Author affiliations: The Roslin Institute, Easter Bush, Scotland, UK (A.B. Diack, V. Pinion, J.C. Manson); University of Edinburgh, Edinburgh, Scotland, UK (D. Ritchie, M. Bishop, R.G. Will); Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob, Universite Pierre et Marie Curie-Paris 6, INSERM, and CNRS, Paris, France (J.-P. Brandel, S. Haik); Fdazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy (F. Tagliavini); Erasmus University Medical School, Rotterdam, the Netherlands (C. Van Duijn); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.D. Belay, L.B. Schonberger); Case Western Reserve University, Cleveland, Ohio, USA (P. Gambetti); and Food and Drug Administration, Rockville, Maryland, USA (P. Piccardo)
Figure 3. . Immunohistochemical detection of abnormal prion protein (PrPSc) in the hippocampus and thalamus of RIII, C57, and VM wild-type mice after inoculation with variant Creutzfeldt-Jakob disease brain tissue. Scale bars = 500 µm. The anti–prion protein detection antibody used was 6H4.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.